USEFULNESS OF SERUM MICRORNAS AS BIOMARKERS FOR PEDIATRIC METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)

被引：0
|
作者：
Blakley, Caroline [1 ]
Nelson, Benjamin [2 ]
Qarooni, Shatha [3 ]
Lee, Wai Han [3 ]
Tryggestad, Jeanie [3 ]
Short, Kevin [3 ]
Palle, Sirish Kumar [3 ]
机构：
[1] Univ Oklahoma, Hlth & Sci Ctr, Norman, OK USA
[2] Harold Hamm Diabet Ctr HHDC, Norman, OK USA
[3] Univ Oklahoma, Hlth Sci Ctr, OUHSC, Dept Pediat, Norman, OK USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
829
引用
收藏
页码：S626 / S626
页数：1
相关论文
共 50 条
  • [41] Nutrients associated with metabolic dysfunction-associated steatotic liver disease
    Jeong, Seogsong
    JOURNAL OF HEPATOLOGY, 2024, 80 (02) : e81 - e82
  • [42] Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Italian women: is liver fibrosis independent from menopause?
    Chen, R.
    Salamone, A.
    Abbati, C.
    Capelli, R.
    Santangeli, E.
    Stefanini, B.
    Indre, M. G.
    Ravaioli, F.
    Piscaglia, F.
    Ferri, S.
    DIGESTIVE AND LIVER DISEASE, 2025, 57
  • [43] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [44] Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases
    Sandireddy, Reddemma
    Sakthivel, Suganya
    Gupta, Priyanka
    Behari, Jatin
    Tripathi, Madhulika
    Singh, Brijesh Kumar
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2024, 12
  • [45] Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents
    Maldonado-Rojas, Andrea del Carmen
    Zuarth-Vazquez, Julia Maria
    Uribe, Misael
    Barbero-Becerra, Varenka J.
    ANNALS OF HEPATOLOGY, 2024, 29 (02)
  • [46] The Role of Endoplasmic Reticulum in Lipotoxicity during Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pathogenesis
    Venkatesan, Nanditha
    Doskey, Luke C.
    Malhi, Harmeet
    AMERICAN JOURNAL OF PATHOLOGY, 2023, 193 (12): : 1887 - 1899
  • [47] Subclinical myocardial fibrosis is related to disease severity in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)
    Nabilou, Puria
    Wiese, Signe
    Hetland, Liv
    Werge, Mikkel
    Thing, Mira
    Rashu, Elias
    Junker, Anders
    Barlose, Mads
    Siebner, Hartwig
    Moller, Soren
    Bendtsen, Flemming
    Gluud, Lise Lotte
    Hove, Jens
    JOURNAL OF HEPATOLOGY, 2024, 80 : S555 - S555
  • [48] THE MOLECULAR BASIS OF THYROID HORMONE RESCUE OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) IN MICE
    Ramanathan, Raghu
    Johnson, Sarah
    Ibdah, Jamal A.
    GASTROENTEROLOGY, 2024, 166 (05) : S1642 - S1642
  • [49] Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
    Singh, Avneet
    Buckholz, Adam
    Kumar, Sonal
    Newberry, Carolyn
    NUTRIENTS, 2024, 16 (05)
  • [50] NAFLD vs MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)-Why the Need for a Change of Nomenclature?
    Gastaldelli, Amalia
    Newsome, Philip N.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2025,
12345